Logo image of NEOG

NEOGEN CORP (NEOG) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NEOG - US6404911066 - Common Stock

6.01 USD
+0.08 (+1.35%)
Last: 12/5/2025, 1:11:09 PM
Fundamental Rating

3

NEOG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. While NEOG seems to be doing ok healthwise, there are quite some concerns on its profitability. NEOG is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

NEOG had positive earnings in the past year.
In the past year NEOG had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: NEOG reported negative net income in multiple years.
NEOG had a positive operating cash flow in each of the past 5 years.
NEOG Yearly Net Income VS EBIT VS OCF VS FCFNEOG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M -800M -1B

1.2 Ratios

NEOG has a Return On Assets (-30.88%) which is comparable to the rest of the industry.
NEOG's Return On Equity of -49.23% is in line compared to the rest of the industry. NEOG outperforms 51.06% of its industry peers.
Industry RankSector Rank
ROA -30.88%
ROE -49.23%
ROIC N/A
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
NEOG Yearly ROA, ROE, ROICNEOG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40

1.3 Margins

The Gross Margin of NEOG (46.39%) is comparable to the rest of the industry.
NEOG's Gross Margin has been stable in the last couple of years.
NEOG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
NEOG Yearly Profit, Operating, Gross MarginsNEOG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

4

2. Health

2.1 Basic Checks

NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NEOG remains at a similar level compared to 1 year ago.
Compared to 5 years ago, NEOG has more shares outstanding
The debt/assets ratio for NEOG is higher compared to a year ago.
NEOG Yearly Shares OutstandingNEOG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
NEOG Yearly Total Debt VS Total AssetsNEOG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

NEOG has an Altman-Z score of 0.78. This is a bad value and indicates that NEOG is not financially healthy and even has some risk of bankruptcy.
NEOG has a Altman-Z score (0.78) which is in line with its industry peers.
A Debt/Equity ratio of 0.37 indicates that NEOG is not too dependend on debt financing.
NEOG's Debt to Equity ratio of 0.37 is in line compared to the rest of the industry. NEOG outperforms 47.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z 0.78
ROIC/WACCN/A
WACC7.61%
NEOG Yearly LT Debt VS Equity VS FCFNEOG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

NEOG has a Current Ratio of 3.58. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.58, NEOG is in the better half of the industry, outperforming 64.89% of the companies in the same industry.
A Quick Ratio of 2.26 indicates that NEOG has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.26, NEOG is in line with its industry, outperforming 56.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.58
Quick Ratio 2.26
NEOG Yearly Current Assets VS Current LiabilitesNEOG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

3

3. Growth

3.1 Past

NEOG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
NEOG shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -10.20% yearly.
Looking at the last year, NEOG shows a decrease in Revenue. The Revenue has decreased by -2.77% in the last year.
Measured over the past years, NEOG shows a quite strong growth in Revenue. The Revenue has been growing by 16.43% on average per year.
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%

3.2 Future

Based on estimates for the next years, NEOG will show a small growth in Earnings Per Share. The EPS will grow by 7.29% on average per year.
NEOG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.76% yearly.
EPS Next Y-25.82%
EPS Next 2Y2.51%
EPS Next 3Y6.43%
EPS Next 5Y7.29%
Revenue Next Year-7.61%
Revenue Next 2Y-3.02%
Revenue Next 3Y-1.03%
Revenue Next 5Y0.76%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NEOG Yearly Revenue VS EstimatesNEOG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
NEOG Yearly EPS VS EstimatesNEOG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 0.4 0.6

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 20.03, the valuation of NEOG can be described as rather expensive.
Based on the Price/Earnings ratio, NEOG is valued cheaply inside the industry as 81.38% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.41. NEOG is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 17.33 indicates a rather expensive valuation of NEOG.
82.98% of the companies in the same industry are more expensive than NEOG, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.40, NEOG is valued rather cheaply.
Industry RankSector Rank
PE 20.03
Fwd PE 17.33
NEOG Price Earnings VS Forward Price EarningsNEOG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NEOG is valued a bit cheaper than 76.60% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 19.68
NEOG Per share dataNEOG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.51%
EPS Next 3Y6.43%

0

5. Dividend

5.1 Amount

No dividends for NEOG!.
Industry RankSector Rank
Dividend Yield N/A

NEOGEN CORP

NASDAQ:NEOG (12/5/2025, 1:11:09 PM)

6.01

+0.08 (+1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-09 2025-10-09/bmo
Earnings (Next)01-08 2026-01-08
Inst Owners112.45%
Inst Owner Change2.38%
Ins Owners0.42%
Ins Owner Change84.05%
Market Cap1.31B
Revenue(TTM)886.89M
Net Income(TTM)-1.04B
Analysts76.36
Price Target7.78 (29.45%)
Short Float %9.67%
Short Ratio4.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)30.72%
Min EPS beat(2)-34.64%
Max EPS beat(2)96.08%
EPS beat(4)2
Avg EPS beat(4)15.53%
Min EPS beat(4)-34.64%
Max EPS beat(4)96.08%
EPS beat(8)2
Avg EPS beat(8)-1.35%
EPS beat(12)4
Avg EPS beat(12)52.58%
EPS beat(16)5
Avg EPS beat(16)29.73%
Revenue beat(2)1
Avg Revenue beat(2)0.03%
Min Revenue beat(2)-0.4%
Max Revenue beat(2)0.46%
Revenue beat(4)1
Avg Revenue beat(4)-0.95%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)0.46%
Revenue beat(8)2
Avg Revenue beat(8)-0.99%
Revenue beat(12)3
Avg Revenue beat(12)-0.84%
Revenue beat(16)3
Avg Revenue beat(16)-1.21%
PT rev (1m)17.31%
PT rev (3m)17.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.33%
EPS NY rev (1m)77.78%
EPS NY rev (3m)-2.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.63%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)0.33%
Valuation
Industry RankSector Rank
PE 20.03
Fwd PE 17.33
P/S 1.47
P/FCF N/A
P/OCF 15.01
P/B 0.62
P/tB N/A
EV/EBITDA 19.68
EPS(TTM)0.3
EY4.99%
EPS(NY)0.35
Fwd EY5.77%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.4
OCFY6.66%
SpS4.08
BVpS9.75
TBVpS-1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number8.11
Profitability
Industry RankSector Rank
ROA -30.88%
ROE -49.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.39%
FCFM N/A
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
F-Score3
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Debt/EBITDA 8.03
Cap/Depr 75.94%
Cap/Sales 10.17%
Interest Coverage N/A
Cash Conversion 88.14%
Profit Quality N/A
Current Ratio 3.58
Quick Ratio 2.26
Altman-Z 0.78
F-Score3
WACC7.61%
ROIC/WACCN/A
Cap/Depr(3y)85.8%
Cap/Depr(5y)97.5%
Cap/Sales(3y)10.58%
Cap/Sales(5y)8.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
EPS Next Y-25.82%
EPS Next 2Y2.51%
EPS Next 3Y6.43%
EPS Next 5Y7.29%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%
Revenue Next Year-7.61%
Revenue Next 2Y-3.02%
Revenue Next 3Y-1.03%
Revenue Next 5Y0.76%
EBIT growth 1Y-147.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.85%
EBIT Next 3Y34.71%
EBIT Next 5Y20.44%
FCF growth 1Y39.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.3%
OCF growth 3Y-5.05%
OCF growth 5Y-7.47%

NEOGEN CORP / NEOG FAQ

What is the fundamental rating for NEOG stock?

ChartMill assigns a fundamental rating of 3 / 10 to NEOG.


Can you provide the valuation status for NEOGEN CORP?

ChartMill assigns a valuation rating of 4 / 10 to NEOGEN CORP (NEOG). This can be considered as Fairly Valued.


How profitable is NEOGEN CORP (NEOG) stock?

NEOGEN CORP (NEOG) has a profitability rating of 3 / 10.


What is the earnings growth outlook for NEOGEN CORP?

The Earnings per Share (EPS) of NEOGEN CORP (NEOG) is expected to decline by -25.82% in the next year.